Treatment of chronic hepatitis C in patients with HIV/HCV coinfection

doi:10.5501/wjv.v4.i1.1

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7161)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

437

WORD

341

HTML

3850

Figures (1-3)

306

Tables (1-2)

553

Sum=5487

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

825

Download

849

Sum=1674

Feb 12, 2015 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Virology. Feb 12, 2015; 4(1): 1-12
Published online Feb 12, 2015. doi: 10.5501/wjv.v4.i1.1

Table 2 Anti-human immunodeficiency virus drugs contraindicated during anti-hepatitis C virus treatment

	Contraindicated anti-HIV drugs
	NRTI	NNRTI	IP	INI	CCR5 antagonist
Alpha interferon	-	-	-	-	-
Ribavirin	Didanosine, stavudine, zidovudine	-	-	-	-
Boceprevir	Didanosine, stavudine, zidovudine	Efavirenz	Lopinavir/r, atazanavir/r, darunavir/r	EVG/cobi/TDF/FTC¹	Maraviroc³
Telaprevir	Didanosine, stavudine, zidovudine	Efavirenz²	Lopinavir/r darunavir/r fosamprenavir/r	-	Maraviroc³
Sofosbuvir	Didanosine, stavudine, zidovudine	-	Tipranavir/r	No data	-
Simeprevir	Didanosine, stavudine, zidovudine	Efavirenz, delavirdine etravirine, nevirapine	All protease inhibitors with or without ritonavir booster	EVG/cobi/TDF/FTC	No data
Daclatasvir	Didanosine, stavudine, zidovudine	Efavirenz⁴, nevirapine, etravirine	Lopinavir/r¹ darunavir/r¹ fosamprenavir/r¹ tipranavir/r	-	-
Ledipasvir	Didanosine, stavudine, zidovudine	Nevirapine¹, etravirine¹	Lopinavir/r¹ fosamprenavir/r¹ tipranavir/r	EVG/cobi/TDF/FTC¹	No data
Dasabuvir/ ombitasvir/ paritaprevir-r	Didanosine, stavudine, zidovudine	Efavirenz, rilpivirine nevirapine¹ etravirine¹	lopinavir/r¹ fosamprenavir/r tipranavir/r¹	EVG/cobi/TDF/FTC¹	No data

¹No data, do not co-administer;

²Increase the dose of telaprevir to 1125 mg three times a day;

³Maraviroc 150 mg twice a day;

⁴Increase the dose of daclatasvir to 90 mg a day. HIV: Hepatitis C virus.

Citation: Coppola N, Martini S, Pisaturo M, Sagnelli C, Filippini P, Sagnelli E. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World J Virology 2015; 4(1): 1-12
URL: https://www.wjgnet.com/2220-3249/full/v4/i1/1.htm
DOI: https://dx.doi.org/10.5501/wjv.v4.i1.1